Evaluating the severity of atopic dermatitis (eczema) objectively.

Monitoring disease progression and treatment response over time.

Standardized reporting in clinical trials for atopic dermatitis therapies.

A: Extent of disease as percentage of Body Surface Area (BSA) affected (0-100).

B: Intensity of 6 specific morphologic lesions (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, and dryness/xerosis) graded 0-3. Max 18.

C: Subjective symptoms (pruritus and sleep loss) over the last 3 days, graded 0-10 on VAS. Max 20.

Dryness (xerosis) is evaluated ONLY on uninvolved skin areas.

It combines both objective physician assessment and subjective patient-reported outcomes, making it very comprehensive.

A score > 50 indicates severe atopic dermatitis.

< 25: Mild disease.

25 - 50: Moderate disease.

> 50: Severe disease. Consider escalation to systemic immunosuppression or biologics.